{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T11:23:51Z","timestamp":1793618631612,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jacl.2024.08.013","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T04:18:18Z","timestamp":1725509898000},"page":"e647-e663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":124,"title":["Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-6303","authenticated-orcid":false,"given":"Daniel E.","family":"Soffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6164-4617","authenticated-orcid":false,"given":"Nicholas A.","family":"Marston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5147-5469","authenticated-orcid":false,"given":"Kevin C.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9456-850X","authenticated-orcid":false,"given":"Vera A.","family":"Bittner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3165-849X","authenticated-orcid":false,"given":"Jessica M.","family":"Pe\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thanassoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth S.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5089-9494","authenticated-orcid":false,"given":"Carol F.","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9541-6954","authenticated-orcid":false,"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave L.","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2473-5549","authenticated-orcid":false,"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jacl.2024.08.013_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacl.2021.09.046","article-title":"Lipid measurements in the management of cardiovascular diseases: practical recommendations a scientific statement from the national lipid association writing group","volume":"15","author":"Wilson","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2024.08.013_bib0002","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0009-3084(94)90142-2","article-title":"Lp(a) catabolism in hypercholesterolaemic individuals","volume":"67-68","author":"Knight","year":"1994","journal-title":"Chem Phys Lipids"},{"issue":"2","key":"10.1016\/j.jacl.2024.08.013_bib0003","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pathol.2018.11.003","article-title":"Lipoprotein(a) catabolism: a case of multiple receptors","volume":"51","author":"McCormick","year":"2019","journal-title":"Pathology"},{"issue":"20","key":"10.1016\/j.jacl.2024.08.013_bib0004","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.025858","article-title":"Physiological bases for the superiority of apolipoprotein B over low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as a marker of cardiovascular risk","volume":"11","author":"Glavinovic","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"11","key":"10.1016\/j.jacl.2024.08.013_bib0005","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1016\/j.metabol.2009.04.040","article-title":"Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects","volume":"58","author":"Otokozawa","year":"2009","journal-title":"Metabolism"},{"issue":"6090","key":"10.1016\/j.jacl.2024.08.013_bib0006","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/323734a0","article-title":"Complete protein sequence and identification of structural domains of human apolipoprotein B","volume":"323","author":"Knott","year":"1986","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jacl.2024.08.013_bib0007","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1529\/biophysj.104.046235","article-title":"Assembly of lipoprotein particles containing apolipoprotein-B: structural model for the nascent lipoprotein particle","volume":"88","author":"Richardson","year":"2005","journal-title":"Biophys J"},{"issue":"9","key":"10.1016\/j.jacl.2024.08.013_bib0008","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI103182","article-title":"The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum","volume":"34","author":"Havel","year":"1955","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2024.08.013_bib0009","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehae258","article-title":"Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention","author":"Sniderman","year":"2024","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacl.2024.08.013_bib0010","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0002-9149(03)00262-5","article-title":"Concordance\/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk","volume":"91","author":"Sniderman","year":"2003","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2024.08.013_bib0011","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11883-009-0054-2","article-title":"ApoB versus non-HDL-C: what to do when they disagree","volume":"11","author":"Sniderman","year":"2009","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"10.1016\/j.jacl.2024.08.013_bib0012","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1373\/clinchem.2016.264515","article-title":"Discordance between circulating atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women","volume":"63","author":"Lawler","year":"2017","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.jacl.2024.08.013_bib0013","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MED.0000000000000389","article-title":"Discordance between lipoprotein particle number and cholesterol content: an update","volume":"25","author":"Cantey","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"11","key":"10.1016\/j.jacl.2024.08.013_bib0014","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"10.1016\/j.jacl.2024.08.013_bib0015","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1161\/CIRCULATIONAHA.104.532499","article-title":"Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men","volume":"112","author":"Pischon","year":"2005","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2024.08.013_bib0016","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1093\/clinchem\/47.4.712","article-title":"Optimization of beta-quantification methods for high-throughput applications","volume":"47","author":"Cole","year":"2001","journal-title":"Clin Chem"},{"issue":"6","key":"10.1016\/j.jacl.2024.08.013_bib0017","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","article-title":"Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge","volume":"18","author":"Friedewald","year":"1972","journal-title":"Clin Chem"},{"issue":"17","key":"10.1016\/j.jacl.2024.08.013_bib0018","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1001\/jama.1986.03380170088024","article-title":"A comparison of methods for the estimation of plasma low- and very low-density lipoprotein cholesterol. The lipid research clinics prevalence study","volume":"256","author":"DeLong","year":"1986","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.jacl.2024.08.013_bib0019","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1001\/jama.2013.280532","article-title":"Comparison of a novel method vs. the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile","volume":"310","author":"Martin","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacl.2024.08.013_bib0020","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jacc.2021.11.042","article-title":"Discordance between standard equations for determination of LDL cholesterol in patients with atherosclerosis","volume":"79","author":"Sajja","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2024.08.013_bib0021","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jacc.2021.12.005","article-title":"LDL-C estimation: the perils of living with imperfection","volume":"79","author":"Maki","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2024.08.013_bib0022","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1001\/jamacardio.2020.0013","article-title":"A new equation for calculation of low-density lipoprotein cholesterol in patients with normolipidemia and\/or hypertriglyceridemia","volume":"5","author":"Sampson","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2024.08.013_bib0023","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.28817","article-title":"Comparison of methods to estimate low-density lipoprotein cholesterol in patients with high triglyceride levels","volume":"4","author":"Sajja","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacl.2024.08.013_bib0024","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.atherosclerosis.2018.06.868","article-title":"Performance of LDL-C calculated with Martin's formula compared to the Friedewald equation in familial combined hyperlipidemia","volume":"277","author":"Mehta","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2024.08.013_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2021.100203","article-title":"Utility of non-HDL-C and apoB targets in the context of new more aggressive lipid guidelines","volume":"7","author":"Quispe","year":"2021","journal-title":"Am J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2024.08.013_bib0026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/clinchem\/hvad190","article-title":"The Sampson-NIH equation is the preferred calculation method for LDL-C","volume":"70","author":"Sampson","year":"2024","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.jacl.2024.08.013_bib0027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/clinchem\/hvac161","article-title":"A translational tool to facilitate use of apolipoprotein B for clinical decision-making","volume":"69","author":"Cole","year":"2023","journal-title":"Clin Chem"},{"key":"10.1016\/j.jacl.2024.08.013_bib0028","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/01.CIR.31.3.321","article-title":"A system for phenotyping hyperlipoproteinemia","volume":"31","author":"Fredrickson","year":"1965","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2024.08.013_bib0029","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJM196701262760406","article-title":"Fat transport in lipoproteins\u2013an integrated approach to mechanisms and disorders","volume":"276","author":"Fredrickson","year":"1967","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacl.2024.08.013_bib0030","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacl.2007.07.006","article-title":"Diagnosis of type III hyperlipoproteinemia from plasma total cholesterol, triglyceride, and apolipoprotein B","volume":"1","author":"Sniderman","year":"2007","journal-title":"J Clin Lipidol"},{"issue":"12","key":"10.1016\/j.jacl.2024.08.013_bib0031","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1001\/jama.1992.03480120090039","article-title":"Blood lipid measurements. Variations and practical utility","volume":"267","author":"Cooper","year":"1992","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jacl.2024.08.013_bib0032","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030405","article-title":"Standardization of apolipoprotein B, LDL-cholesterol, and non-HDL-cholesterol","volume":"12","author":"Contois","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacl.2024.08.013_bib0033","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3343\/alm.2024.44.1.6","article-title":"Bias in laboratory medicine: the dark side of the moon","volume":"44","author":"Coskun","year":"2024","journal-title":"Ann Lab Med"},{"issue":"6","key":"10.1016\/j.jacl.2024.08.013_bib0034","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","article-title":"Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures","volume":"56","author":"Miller","year":"2010","journal-title":"Clin Chem"},{"issue":"4","key":"10.1016\/j.jacl.2024.08.013_bib0035","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/clinchem\/40.4.586","article-title":"International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material","volume":"40","author":"Marcovina","year":"1994","journal-title":"Clin Chem"},{"issue":"3","key":"10.1016\/j.jacl.2024.08.013_bib0036","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/clinchem\/hvac204","article-title":"Development of an LC-MRM-MS-based candidate reference measurement procedure for standardization of serum apolipoprotein (a) tests","volume":"69","author":"Ruhaak","year":"2023","journal-title":"Clin Chem"},{"issue":"2","key":"10.1016\/j.jacl.2024.08.013_bib0037","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jacc.2015.10.055","article-title":"Discordance between apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study","volume":"67","author":"Wilkins","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2024.08.013_bib0038","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.atherosclerosis.2012.08.039","article-title":"Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study","volume":"225","author":"Sniderman","year":"2012","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.jacl.2024.08.013_bib0039","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/jama.2017.11467","article-title":"Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk","volume":"318","author":"Ference","year":"2017","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jacl.2024.08.013_bib0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jacl.2007.10.001","article-title":"LDL particle number and risk of future cardiovascular disease in the Framingham offspring study - implications for LDL management","volume":"1","author":"Cromwell","year":"2007","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.jacl.2024.08.013_bib0041","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1161\/CIRCULATIONAHA.108.816181","article-title":"Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women","volume":"119","author":"Mora","year":"2009","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2024.08.013_bib0042","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","article-title":"Clinical implications of discordance between low-density lipoprotein cholesterol and particle number","volume":"5","author":"Otvos","year":"2011","journal-title":"J Clin Lipidol"},{"issue":"7","key":"10.1016\/j.jacl.2024.08.013_bib0043","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/2047487312465523","article-title":"Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: the ARIC study","volume":"21","author":"Ndumele","year":"2014","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2024.08.013_bib0044","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1177\/2047487315569411","article-title":"Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham heart study beyond LDL-C and non-HDL-C","volume":"22","author":"Pencina","year":"2015","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2024.08.013_bib0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","article-title":"Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease","volume":"140","author":"Welsh","year":"2019","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacl.2024.08.013_bib0046","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2024.08.013_bib0047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003062","article-title":"Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis","volume":"17","author":"Richardson","year":"2020","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.jacl.2024.08.013_bib0048","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/jama.2017.11750","article-title":"Genetic studies help clarify the complexities of lipid biology and treatment","volume":"318","author":"Sniderman","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jacl.2024.08.013_bib0049","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1001\/jama.2018.20045","article-title":"Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease","volume":"321","author":"Ference","year":"2019","journal-title":"JAMA"},{"issue":"25","key":"10.1016\/j.jacl.2024.08.013_bib0050","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.jacl.2024.08.013_bib0051","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacl.2024.08.013_bib0052","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacl.2024.08.013_bib0053","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.97.15.1453","article-title":"Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the scandinavian simvastatin survival study (4S)","volume":"97","author":"Pedersen","year":"1998","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jacl.2024.08.013_bib0054","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1080\/07853890801964955","article-title":"Lipoprotein predictors of cardiovascular events in statin-treated patients with coronary heart disease. Insights from the incremental decrease in end-points through aggressive lipid-lowering trial (IDEAL)","volume":"40","author":"Holme","year":"2008","journal-title":"Ann Med"},{"issue":"23","key":"10.1016\/j.jacl.2024.08.013_bib0055","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"issue":"17","key":"10.1016\/j.jacl.2024.08.013_bib0056","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jacc.2011.12.035","volume":"59","author":"Mora","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2024.08.013_bib0057","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1161\/ATVBAHA.108.181735","article-title":"Prognostic utility of apoB\/AI, total cholesterol\/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22","volume":"29","author":"Ray","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"9","key":"10.1016\/j.jacl.2024.08.013_bib0058","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1161\/CIRCULATIONAHA.121.057807","article-title":"Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of alirocumab","volume":"146","author":"Hagstrom","year":"2022","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacl.2024.08.013_bib0059","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1001\/jama.2012.366","article-title":"Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis","volume":"307","author":"Boekholdt","year":"2012","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jacl.2024.08.013_bib0060","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000759","article-title":"Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials","volume":"3","author":"Thanassoulis","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"25","key":"10.1016\/j.jacl.2024.08.013_bib0061","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.jacl.2024.08.013_bib0062","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology solution set oversight committee","volume":"80","author":"Writing","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.jacl.2024.08.013_bib0063","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.115.016857","volume":"132","author":"Mora","year":"2015","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacl.2024.08.013_bib0064","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jacl.2007.12.006","article-title":"Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice","volume":"2","author":"Sniderman","year":"2008","journal-title":"J Clin Lipidol"},{"issue":"23","key":"10.1016\/j.jacl.2024.08.013_bib0065","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/j.jacc.2024.03.423","article-title":"Excess apolipoprotein B and cardiovascular risk in women and men","volume":"83","author":"Johannesen","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2024.08.013_bib0066","first-page":"e596","article-title":"2019 ACC\/AHA Guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacl.2024.08.013_bib0067","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacl.2023.05.099","article-title":"Nutrition interventions for adults with dyslipidemia: a clinical perspective from the national lipid association","volume":"17","author":"Kirkpatrick","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2024.08.013_bib0068","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacl.2024.08.013_bib0069","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.4158\/CS-2020-0490","article-title":"Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the management of dyslipidemia and prevention of cardiovascular disease algorithm - 2020 executive summary","volume":"26","author":"Handelsman","year":"2020","journal-title":"Endocr Pract"},{"issue":"8","key":"10.1016\/j.jacl.2024.08.013_bib0070","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2024.08.013_bib0071","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacl.2015.02.003","article-title":"National lipid association recommendations for patient-centered management of dyslipidemia: part 1\u2014Full report","volume":"9","author":"Jacobson","year":"2015","journal-title":"J Clin Lipidol"},{"issue":"9","key":"10.1016\/j.jacl.2024.08.013_bib0072","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/M19-0203","article-title":"The chylomicronemia syndrome is most often multifactorial: a narrative review of causes and treatment","volume":"170","author":"Chait","year":"2019","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.jacl.2024.08.013_bib0073","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1210\/clinem\/dgac503","article-title":"Dysbetalipoproteinemia is associated with increased risk of coronary and peripheral vascular disease","volume":"108","author":"Paquette","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jacl.2024.08.013_bib0074","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2024.08.013_bib0075","series-title":"Lipoprotein X-Induced Hyperlipidemia","author":"Ashorobi","year":"2024"},{"key":"10.1016\/j.jacl.2024.08.013_bib0076","unstructured":"Shapiro M.D., Feingold K.R. Monogenic disorders altering HDL levels. In: Feingold K.R., Anawalt B., Blackman M.R., et al. (eds.), Endotext. MDText.com; 2024."},{"issue":"3","key":"10.1016\/j.jacl.2024.08.013_bib0077","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jacl.2019.05.009","article-title":"Elevated apolipoprotein B as a risk-enhancing factor in 2018 cholesterol guidelines","volume":"13","author":"Grundy","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2024.08.013_bib0078","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jacl.2020.04.011","article-title":"Genetic testing in dyslipidemia: a scientific statement from the national lipid association","volume":"14","author":"Brown","year":"2020","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.jacl.2024.08.013_bib0079","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/ncpendmet0982","article-title":"A diagnostic algorithm for the atherogenic apolipoprotein B dyslipoproteinemias","volume":"4","author":"de Graaf","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.jacl.2024.08.013_bib0080","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrendo.2010.50","article-title":"Diagnosis and treatment of apolipoprotein B dyslipoproteinemias","volume":"6","author":"Sniderman","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.jacl.2024.08.013_bib0081","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jacl.2018.09.006","article-title":"The spectrum of type III hyperlipoproteinemia","volume":"12","author":"Sniderman","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"1","key":"10.1016\/j.jacl.2024.08.013_bib0082","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12944-021-01585-8","article-title":"A new phenotypic classification system for dyslipidemias based on the standard lipid panel","volume":"20","author":"Sampson","year":"2021","journal-title":"Lipids Health Dis"},{"issue":"22","key":"10.1016\/j.jacl.2024.08.013_bib0083","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1161\/CIRCULATIONAHA.105.588178","article-title":"Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy","volume":"112","author":"Denke","year":"2005","journal-title":"Circulation"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742400240X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S193328742400240X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T06:33:28Z","timestamp":1732602808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S193328742400240X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S193328742400240X"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2024.08.013","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2024.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}